Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968744 | 0.83 | — | — | |
| SCHEMBL16870529 | 0.83 | GRIN2D (0.45) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12228571 | 0.83 | — | — | |
| SCHEMBL7876288 | 0.79 | ANPEP (0.40) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7887552 | 0.79 | ANPEP (0.40) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8382393 | 0.79 | ANPEP (0.40) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30308811 | 0.79 | ANPEP (0.40) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| Dimethylamine SCHEMBL28626358 | 0.75 | SIGMAR1 (0.43) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7174206 | 0.74 | GRIN2D (0.42) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7130225 | 0.74 | GRIN2D (0.42) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025029623-A2 | LIGHT-TRIGGERED POLYMER-NALOXONE CONJUGATE FOR OPIOID REVERSAL | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-2907525-B1 | DIBENZOCYCLOOCTENE-COMPOUNDS FOR BIOORTHOGONAL REACTIONS | UNIV GEORGIA (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9932297-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932297-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170320815-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9758671-B2 | Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition | BECKER MATTHEW (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758671-B2 | Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition | BECKER MATTHEW (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758671-B2 | Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition | BECKER MATTHEW (US) | 2017-09-12 | — | — | US | disclosed |
| US-9725405-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725405-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | KDM1A 1424/4885GRIN2D 1022/4885GRIN3B 424/4885 |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | KDM1A 1424/4885GRIN2D 1022/4885GRIN3B 424/4885 |
| US-20170320815-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | KDM1A 1424/4885GRIN2D 1022/4885GRIN3B 424/4885 |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | KDM1A 1424/4885GRIN2D 1022/4885GRIN3B 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.